Ligand Pharmaceuticals Reports Strong 2025 Financials, Driven by Strategic Royalty Investments and Pelthos Transaction

summarizeSummary

Ligand Pharmaceuticals reported strong 2025 financial results with significant revenue and net income growth, driven by strategic royalty acquisitions and a major convertible note offering.

check_boxKey Events

• Strong Financial Performance in 2025

  Total revenue and income increased by 60% to $268.1 million in 2025 from $167.1 million in 2024. Net income from continuing operations was $124.5 million in 2025, a significant improvement from a $4.0 million net loss in 2024, with basic EPS of $6.44.

• Successful Pelthos Transaction

  The company recognized $53.1 million in income from the disposition of its LNHC, Inc. subsidiary (Pelthos Therapeutics business) in July 2025. Ligand retains approximately 48% ownership of Pelthos common stock and is entitled to a 13% royalty on worldwide sales of Zelsuvmi, a newly launched FDA-approved product for molluscum contagiosum.

• Issued $460M Convertible Senior Notes

  In August 2025, Ligand issued $460 million in 0.75% convertible senior notes due 2030, generating net proceeds of $445.1 million. The company used $15 million of these proceeds to repurchase 102,034 shares of its common stock at $147.01 per share, and entered into convertible note hedge and warrant transactions to manage potential dilution.

• Expanded Royalty Portfolio with New Investments

  Ligand made several new strategic investments in 2025, including $50 million in Castle Creek Biosciences for D-Fi gene therapy royalties, up to $40 million in Orchestra BioMed for cardiology program royalties, $7 million in Arecor for biosimilar product royalties, and $1 million in LeonaBio common stock and warrants.

auto_awesomeAnalysis

This annual report details Ligand Pharmaceuticals' robust financial performance in 2025, marked by significant revenue and net income growth, a turnaround from a net loss in the prior year. The company successfully executed several strategic transactions, including the Pelthos Transaction which generated substantial income and a new 13% royalty stream. A major capital raise through $460 million in convertible senior notes, coupled with new royalty investments in Castle Creek, Orchestra BioMed, and Arecor, underscores the company's active portfolio expansion and financial strength. While an impairment loss on Agenus partner programs is noted, the overall strategic execution and financial results are highly positive, providing a comprehensive view of the company's royalty-focused business model.